New CSF Biomarker Fragment Could Transform Narcolepsy Type 1 Diagnosis
A truncated orexin-A fragment outperforms full-length hypocretin-1 in distinguishing narcolepsy type 1 patients from controls.
Sleep optimization, mindfulness practices, stress reduction, and their impact on longevity
346 articles
A truncated orexin-A fragment outperforms full-length hypocretin-1 in distinguishing narcolepsy type 1 patients from controls.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A selective D3 receptor ligand reduces leg movement symptoms and improves sleep quality in a rat model of restless legs syndrome.
Adults with stronger circadian rest-activity patterns show measurable signs of slower biological aging in blood-based biomarkers.
The FINI instrument measures six key life domains in narcolepsy patients, offering clinicians a richer picture than sleepiness scales alone.
Scientists pinpoint the ventral hippocampus-amygdala pathway as the neural switch that turns traumatic memories into sleep disruption.
A bibliometric analysis of 595 papers maps how glymphatic-Alzheimer's research has grown exponentially, pinpointing AQP4, sleep, and DTI-ALPS imaging as the hottest frontiers.
A clinical trial finds 10 sessions of low-frequency rTMS improve sleep, glymphatic function, and cognition in chronic insomnia patients.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
A massive Samsung Galaxy Watch study maps real-world sleep patterns across adulthood, revealing who sleeps least and why it matters.
A major review reveals how the glymphatic system's failure drives neurodegeneration and brain tumor resistance — and how to fix it.